Page 108 - ITPS-7-3

INNOSC Theranostics and
Pharmacological Sciences Alpha-2A receptor agonist and addiction

2019;173(3):234-243. anesthesiologists returning to practice. J Addict Med.
2011;5(4):279-283.
doi: 10.1001/jamapediatrics.2018.5044
doi: 10.1097/ADM.0b013e31821852a0
17. Lester BM, Tronick EZ, LaGasse L, et al. The maternal
lifestyle study: Effects of substance exposure during 28. Gold MS, Kleber HD. A rationale for opioid withdrawal
pregnancy on neurodevelopmental outcome in 1-month- symptomatology. Drug Alcohol Depend. 1979;4(5):419-424.
old infants. Pediatrics. 2002;110(6):1182-1192.
doi: 10.1016/0376-8716(79)90074-7
doi: 10.1542/peds.110.6.1182
29. Roth RH, Elsworth JD, Redmond DE Jr. Clonidine
18. Oesterle TS, Thusius NJ, Rummans TA, Gold MS. suppression of noradrenergic hyperactivity during morphine
Medication-assisted treatment for opioid-use disorder. withdrawal by clonidine: Biochemical studies in rodents and
Mayo Clin Proc. 2019;94(10):2072-2086. primates. J Clin Psychiatry. 1982;43(6 Pt 2):42-46.
doi: 10.1016/j.mayocp.2019.03.029 30. Gold MS, Pottash AC, Sweeney DR, Extein I, Annitto WJ.
Opioid detoxification with lofexidine. Drug Alcohol Depend.
19. Rhee TG, Rosenheck RA. Use of drug treatment services
among adults with opioid use disorder: Rates, patterns, and 1981;8(4):307-315.
correlates. Psychiatr Serv. 2019;70(11):992-999. doi: 10.1016/0376-8716(81)90040-5
doi: 10.1176/appi.ps.201900163 31. Pergolizzi JV Jr., Annabi H, Gharibo C, LeQuang JA. The
role of lofexidine in management of opioid withdrawal. Pain
20. McLellan AT, Skipper GS, Campbell M, DuPont RL. Five
year outcomes in a cohort study of physicians treated Ther. 2019;8(1):67-78.
for substance use disorders in the United States. BMJ. doi: 10.1007/s40122-018-0108-7
2008;337:a2038.
32. Kosten TR, O’Connor PG. Management of drug and alcohol
doi: 10.1136/bmj.a2038 withdrawal. N Engl J Med. 2003;348(18):1786-1795.
21. DuPont RL, McLellan AT, White WL, Merlo LJ, Gold MS. doi: 10.1056/NEJMra020617
Setting the standard for recovery: Physicians’ health 33. Zornetzer SF, Gold MS. The locus coeruleus: Its possible role
programs. J Subst Abuse Treat. 2009;36(2):159-171.
in memory consolidation. Physiol Behav. 1976;16(3):331-336.
doi: 10.1016/j.jsat.2008.01.004
doi: 10.1016/0031-9384(76)90140-2
22. Merlo LJ, Campbell MD, Skipper GE, Shea CL, DuPont RL. 34. Gold MS, Redmond DE Jr., Kleber HD. Clonidine
Outcomes for physicians with opioid dependence treated blocks acute opioid-withdrawal symptoms. Lancet.
without agonist pharmacotherapy in physician health 1978;2(8090):599-602.
programs. J Subst Abuse Treat. 2016;64:47-54.
doi: 10.1016/s0140-6736(78)92823-4
doi: 10.1016/j.jsat.2016.02.004
35. Gold MS, Dackis CA. The Discovery of Clonidine’s Action
23. Buhl A, Oreskovich MR, Meredith CW, Campbell MD, in Opioid Withdrawal. Munich: Catapressan, Arsneimittel-
Dupont RL. Prognosis for the recovery of surgeons from Forschung; 1983. p. 155-175.
chemical dependency: A 5-year outcome study. Arch Surg.
2011;146(11):1286-1291. 36. Gold MS. Opioid addiction and the locus coeruleus. The
clinical utility of clonidine, naltrexone, methadone, and
doi: 10.1001/archsurg.2011.271
buprenorphine. Psychiatr Clin North Am. 1993;16(1):61-73.
24. Bell J, Strang J. Medication treatment of opioid use disorder. 37. Kleber HD, Gold MS, Riordan CE. The use of clonidine in
Biol Psychiatry. 2020;87(1):82-88.
detoxification from opioids. Bull Narc. 1980;32(2):1-10.
doi: 10.1016/j.biopsych.2019.06.020
38. Gold MS, Roehrich H. Treatment of opioid withdrawal with
25. Merlo LJ, Gold MS. Prescription opioid abuse and clonidine. ISI Atlas of Science. Pharmacology. 1987;1741:29-32.
dependence among physicians: Hypotheses and treatment. 39. Gold MS, De R. Pharmacological activation and inhibition of
Harv Rev Psychiatry. 2008;16(3):181-194.
noradrenergic activity after specific behaviors in nonhuman
doi: 10.1080/10673220802160316 primates. Soc Neurosci. 1977;3(783):250.
26. Merlo LJ, Greene WM. Physician views regarding substance 40. De R, Hwang Y, Gold MS. Anxiety: The locus coeruleus
use-related participation in a state physician health program. connection. Soc Neurosci. 1977;3.
Am J Addict. 2010;19(6):529-533.
41. Redmond DE, Gold MS, Huang YH. Enkephalin Acts to
doi: 10.1111/j.1521-0391.2010.00088.x Inhibit Locus Coeruleus Mediated Behaviors. In: Society for
Neuroscience Abstracts; 1978. p. 4.
27. Merlo LJ, Greene WM, Pomm R. Mandatory naltrexone
treatment prevents relapse among opioid-dependent 42. Gold MS, Redmond DE Jr., Kleber HD. Noradrenergic

Volume 7 Issue 3 (2024) 14 doi: 10.36922/itps.1918